CREST-E HD Study: Creatine Safety, Tolerability and Efficacy in Huntington’s
Carolyn Drazinic, M.D., Ph.D.,
Medical Director of the University of Connecticut Health Center Huntington’s
Disease Program along with the Huntington Study Group (HSG), is conducting a
Phase III clinical trial to study how creatine monohydrate effects people18
years of age and older who have early signs of Huntington’s disease (HD).
CREST-E is designed to look at if high doses of a pure-grade creatine
monohydrate can slow down the decline that occurs in HD patients, by comparing
it to a placebo (looks like study drug but has no active ingredient). CREST-E is
designed to evaluate how safe creatine is and how the body will react to
creatine. It will also look at how creatine affects the body.
Even though many people take creatine at lower doses, the high-doses being
studied here have not been used before and so monitoring its safety at study
visits is an important part of this study.
Over 50 research centers around the world will enroll up to 650 subjects.
This study is sponsored by the National Institutes of Health (NIH) and the
Center for Complementary and Alternative Medicine (NCCAM).
For more information visit
www.clinicaltrials.gov (NCT00712426) or call Bonnie L. Hennig, M.S.W., LCSW,
QCSW, DCSW, at 860-679-4441.